Princeton Alpha Management’s Pacira BioSciences PCRX Stock Holding History

Princeton Alpha Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-8,400	Closed	-$271K	–	702
2016 Q4	$271K	Buy	+8,400	New	+$280K	0.06%	501
2016 Q3	–	Sell	-6,008	Closed	-$203K	–	889
2016 Q2	$203K	Buy	+6,008	New	+$295K	0.04%	671

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

DCM

Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Princeton Alpha Management's PCRX Position: Q1 2017 in Review

Princeton Alpha Management sold out of Pacira BioSciences (PCRX) in Q1 2017, closing a stake of 8,400 shares — an estimated $271K sold.

Princeton Alpha Management first reported a position in PCRX in Q2 2016 and held it in 2 quarters. The position peaked at $271K in Q4 2016. 192 funds tracked by Wall St. Rank hold PCRX as of Q1 2017.

Princeton Alpha Management reported no remaining Pacira BioSciences position as of Q1 2017 after selling out during the quarter.
Princeton Alpha Management sold 8,400 Pacira BioSciences shares in Q1 2017, an estimated $271K.
Princeton Alpha Management first reported a position in Pacira BioSciences in Q2 2016 and held it in 2 quarters.
Princeton Alpha Management's Pacira BioSciences position peaked at $271K in Q4 2016.
192 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2017.

Based on Princeton Alpha Management's 13F filing for Q1 2017, filed 3 May 2017.